Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
and neurological disorders, today announced the successful closing of a $60 million Series A financing. The strong investor demand reflects the high quality of the company's clinical and preclinical pipeline. Gilgamesh Pharmaceuticals (PRNewsfoto/Gilgamesh Pharmaceuticals) This is the first formal capital raise for Gilgamesh Pharma, the spinout formed following the acquisition of Gilgamesh Pharmaceuticals and bretisilocin by AbbVie in 2025 (the "Acquisition"). The new company is led by the same management team and inherits all programs not acquired by AbbVie, as well as capital from the Acquisition and previous neuroplastogen collaboration and option-to-license deal with AbbVie initiated in 2024 (the "Collaboration"). Proceeds from this additional financing will support the advancement of Gilgamesh Pharma's portfolio of novel neuropsychiatric therapeutics, all of which are novel chemical entities (NCEs) with composition of matter IP, as well as the continued expansion of the com
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie: Strong 2026 Outlook, Expect Dividend Increases [Seeking Alpha]Seeking Alpha
- AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting [Yahoo! Finance]Yahoo! Finance
- AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual MeetingPR Newswire
- Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)PR Newswire
- Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC MonacoPR Newswire
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/23/26 - Form ARS
- 3/23/26 - Form DEFA14A
- ABBV's page on the SEC website